Literature DB >> 18949355

Dual topology of functional Toll-like receptor 3 expression in human hepatocellular carcinoma: differential signaling mechanisms of TLR3-induced NF-kappaB activation and apoptosis.

Kentaro Yoneda1, Kazushi Sugimoto, Katsuya Shiraki, Junichiro Tanaka, Tetsuya Beppu, Hiroyuki Fuke, Norihiko Yamamoto, Masahiro Masuya, Ryo Horie, Kazuhiko Uchida, Yoshiyuki Takei.   

Abstract

Toll-like receptor 3 (TLR3) is a pattern-recognizing receptor that is involved in immune signaling and plays a crucial role in survival by being able to recognize various viral components including double-stranded RNA (dsRNA). TLR3 expression and function in cancer cells are not well understood. We investigated the expression of TLR3 in hepatocellular carcinoma (HCC) cells and the function of TLR3 signaling by stimulation and transfection with polyinosinic-polycytidylic acid (Poly I:C), a synthetic form of dsRNA. TLR3 mRNA was expressed in HCC tissues as well as in non-tumor tissues. Positive immunohistochemical staining for TLR3 was observed in 52.7% of HCC tissues, and in HCC cells we found both membranous and cytoplasmic expression of TLR3. While cell surface stimulation of TLR3 with Poly I:C did not affect cell viability, it did activate NF-kappaB levels. In contrast, cytoplasmic stimulation with transfected Poly I:C significantly induced apoptosis accompanied by the down-regulation of anti-apoptotic protein. Transfected Poly I:C also synergistically augmented TRAIL-induced apoptosis, but only with low levels of transfected Poly I:C was IFN-beta production not observed. In conclusion, our results indicate that TLR3 expression in HCC plays an important role with regard to cell survival and proapoptotic activity. Endogenously expressed TLR3 may provide new clinical prospects for TLR3 agonists as cytotoxic agents in HCC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18949355

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  32 in total

1.  Small interfering RNAs induce target-independent inhibition of tumor growth and vasculature remodeling in a mouse model of hepatocellular carcinoma.

Authors:  Mathieu Bergé; Philippe Bonnin; Eric Sulpice; José Vilar; David Allanic; Jean-Sébastien Silvestre; Bernard I Lévy; Gordon C Tucker; Gérard Tobelem; Tatyana Merkulova-Rainon
Journal:  Am J Pathol       Date:  2010-10-22       Impact factor: 4.307

2.  Suppression of human hepatoma (HepG2) cell growth by nuclear factor-kappaB/p65 specific siRNA.

Authors:  Wei Wu; Dengfu Yao; Yilang Wang; Liwei Qiu; Wenli Sai; Junling Yang; Ninghua Yao; Shanshan Li; Yinzhu Bian; Zhiwei Wang; Dengbing Yao
Journal:  Tumour Biol       Date:  2010-07-14

3.  The dual role of TLR3 in metastatic cell line.

Authors:  Tanja Matijevic; Jasminka Pavelic
Journal:  Clin Exp Metastasis       Date:  2011-07-07       Impact factor: 5.150

4.  Toll-like receptor (TLR) 3 immune modulation by unformulated small interfering RNA or DNA and the role of CD14 (in TLR-mediated effects).

Authors:  Cordula Weber; Christian Müller; Anja Podszuweit; Carmen Montino; Jörg Vollmer; Alexandra Forsbach
Journal:  Immunology       Date:  2012-05       Impact factor: 7.397

5.  Innate adjuvant receptor Toll-like receptor 3 can promote breast cancer through cell surface.

Authors:  Banashree Bondhopadhyay; Anuradha Moirangthem; Anupam Basu
Journal:  Tumour Biol       Date:  2014-10-28

6.  Toll-like receptor 9 activation by CpG oligodeoxynucleotide 7909 enhances the radiosensitivity of A549 lung cancer cells via the p53 signaling pathway.

Authors:  Sujuan Yuan; Tiankui Qiao; Xuan Li; Xibing Zhuang; Wei Chen; Xue Chen; Qi Zhang
Journal:  Oncol Lett       Date:  2018-01-31       Impact factor: 2.967

Review 7.  Immunomodulatory effects of dsRNA and its potential as vaccine adjuvant.

Authors:  Bo Jin; Tao Sun; Xiao-Hong Yu; Chao-Qun Liu; Ying-Xiang Yang; Ping Lu; Shan-Feng Fu; Hui-Bin Qiu; Anthony E T Yeo
Journal:  J Biomed Biotechnol       Date:  2010-07-05

Review 8.  TLR agonists: our best frenemy in cancer immunotherapy.

Authors:  Sabina Kaczanowska; Ann Mary Joseph; Eduardo Davila
Journal:  J Leukoc Biol       Date:  2013-03-08       Impact factor: 4.962

9.  Toll-like receptor 3 genetic variants and susceptibility to hepatocellular carcinoma and HBV-related hepatocellular carcinoma.

Authors:  Guanggang Li; Zhendong Zheng
Journal:  Tumour Biol       Date:  2013-02-13

10.  Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment.

Authors:  Yusuke Sato; Yasufumi Goto; Norihiko Narita; Dave S B Hoon
Journal:  Cancer Microenviron       Date:  2009-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.